IPEX Observational Study on Pancreatic Exocrine Insufficiency in IPMN Patients
Summary
NIH registered the IPEX study (NCT07535125), a multicenter prospective observational cohort study evaluating pancreatic exocrine insufficiency (PEI) prevalence in patients with intraductal papillary mucinous neoplasms (IPMN) under surveillance. The study will assess whether PEI correlates with morphologic disease progression and whether it can serve as a functional marker complementary to imaging criteria in IPMN surveillance.
What changed
The IPEX study (NCT07535125) has been registered on ClinicalTrials.gov as a multicenter prospective observational cohort study. The study focuses on intraductal papillary mucinous neoplasms (IPMN), pancreatic cystic neoplasms typically managed through imaging-based surveillance. The research will evaluate whether pancreatic exocrine insufficiency (PEI) is prevalent in IPMN patients and whether PEI correlates with morphologic disease progression.
Healthcare providers and clinical investigators conducting pancreatic surveillance should be aware that PEI may represent an underrecognized complication of IPMN pathophysiology, which includes ductal obstruction by mucin, chronic ductal hypertension, and progressive parenchymal atrophy. The study findings may inform future complementary functional markers for IPMN surveillance protocols.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Observational NCT07535125 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk. However, IPMN pathophysiology includes ductal obstruction by mucin, chronic ductal hypertension, and progressive parenchymal atrophy, mechanisms that may lead to pancreatic exocrine insufficiency (PEI).
PEI is a maldigestion syndrome typically associated with chronic pancreatitis, pancreatic cancer, and pancreatic surgery, but it has never been systematically investigated in patients with IPMN under surveillance.
The IPEX study is a multicenter prospective observational cohort study designed to evaluate whether PEI is prevalent in IPMN patients and whether it correlates with morphologic disease progression. The study also evaluates the potential role of PEI as a functional marker complementary to imaging criteria in IPMN surveillance.
Conditions: Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.